These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 30943154)

  • 1. [The long path (s) of placing medicines on the market].
    Duguet C
    Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():13-17. PubMed ID: 30943154
    [No Abstract]   [Full Text] [Related]  

  • 2. Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D.
    Farid SS; Baron M; Stamatis C; Nie W; Coffman J
    MAbs; 2020; 12(1):1754999. PubMed ID: 32449439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The course of the drug, clinical research and commercialization. Constraints, obstacles, delays and costs].
    Giri I; Rouillon F
    Encephale; 2006 Oct; 32(5 Pt 3):S858-60. PubMed ID: 17119487
    [No Abstract]   [Full Text] [Related]  

  • 4. Cutting the cost of drug development?
    Rawlins MD
    Nat Rev Drug Discov; 2004 Apr; 3(4):360-4. PubMed ID: 15060531
    [No Abstract]   [Full Text] [Related]  

  • 5. Can affordability and innovation coexist for medicines?
    Colbert A; Rintoul A; Simão M; Hill S; Swaminathan S
    BMJ; 2020 Jan; 368():l7058. PubMed ID: 31932276
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmaceutical pricing conundrum: time to get rid of it?
    Garattini L; Padula A
    Eur J Health Econ; 2018 Nov; 19(8):1035-1038. PubMed ID: 30030646
    [No Abstract]   [Full Text] [Related]  

  • 7. Costing drug development.
    Nat Rev Drug Discov; 2003 Apr; 2(4):247. PubMed ID: 12680358
    [No Abstract]   [Full Text] [Related]  

  • 8. [Developability assessment with case studies highlighting the decision taking].
    Dumas J; Sévérac A; Lemoine C; Huille S; Rak A; Prades C
    Med Sci (Paris); 2019 Dec; 35(12):1171-1174. PubMed ID: 31903933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Description of the French players from Avenir's investment program: the role of MabDesign].
    Groux N; Pontremoli R; Vuddamalay G; Richard G; Pons D
    Med Sci (Paris); 2019 Dec; 35(12):1198-1201. PubMed ID: 31903939
    [No Abstract]   [Full Text] [Related]  

  • 10. Oncology drug market worth predicted to increase.
    Burki TK
    Lancet Oncol; 2015 Jan; 16(1):e10. PubMed ID: 25638545
    [No Abstract]   [Full Text] [Related]  

  • 11. Future trends in outsourcing: a summary of the Bioanalysis Zone Survey.
    Craddock A; Nadarajah S
    Bioanalysis; 2017 Aug; 9(15):1127-1129. PubMed ID: 28766363
    [No Abstract]   [Full Text] [Related]  

  • 12. Research on green supply chain coordination strategy for uncertain market demand.
    Cao J; Chen Y; Lu B; Tong C; Zhou G
    Pak J Pharm Sci; 2015 Mar; 28(2 Suppl):687-92. PubMed ID: 25796145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lead Essay: Money, Equity and Access to Medicines.
    Ghinea N; Lipworth W; Kerridge I
    J Bioeth Inq; 2020 Mar; 17(1):25-27. PubMed ID: 32124176
    [No Abstract]   [Full Text] [Related]  

  • 14. A new approach to drug development.
    Brown S
    N Engl J Med; 2006 Nov; 355(19):2045; author reply 2046. PubMed ID: 17099948
    [No Abstract]   [Full Text] [Related]  

  • 15. Model-Informed Drug Development: A Regulatory Perspective on Progress.
    Zhu H; Huang SM; Madabushi R; Strauss DG; Wang Y; Zineh I
    Clin Pharmacol Ther; 2019 Jul; 106(1):91-93. PubMed ID: 31162631
    [No Abstract]   [Full Text] [Related]  

  • 16. Accounting for US public funding in drug development: how can we better balance access, affordability, and innovation?
    Sarpatwari A; Avorn J; Kesselheim AS
    BMJ; 2020 Oct; 371():m3841. PubMed ID: 33032982
    [No Abstract]   [Full Text] [Related]  

  • 17. [The financing and price regulation of drugs in the Spanish National Health System: changes and continuity].
    Puig-Junoy J
    Gac Sanit; 2007; 21(1):1-4. PubMed ID: 17306178
    [No Abstract]   [Full Text] [Related]  

  • 18. New estimates of drug development costs.
    Frank RG
    J Health Econ; 2003 Mar; 22(2):325-30. PubMed ID: 12606149
    [No Abstract]   [Full Text] [Related]  

  • 19. Real-world evidence-What is it and does it matter for approval of drugs?
    Eaglstein WH
    J Am Acad Dermatol; 2018 Aug; 79(2):390-391. PubMed ID: 29410344
    [No Abstract]   [Full Text] [Related]  

  • 20. Bullying biosimilars: cheaper drugs stymied in USA.
    The Lancet Gastroenterology Hepatology
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):371. PubMed ID: 29739669
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.